

ATL 1102

Cat. No.: HY-153481
CAS No.: 350263-41-1
Target: Integrin
Pathway: Cytoskeleton
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

ATL 1102

BIOLOGICAL ACTIVITY

Description

ATL 1102 is a novel second-generation antisense oligonucleotide to CD49d mRNA

REFERENCES

- [1]. Duchartre Y, Bachl S, Kim HN, et al. Effects of CD49d-targeted antisense-oligonucleotide on $\alpha 4$ integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. *PLoS One*. 2017;12(11):e0187684.
- [2]. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS [published correction appears in *Neurology*. 2015 Jan 6;84(1):105]. *Neurology*. 2014;83(20):1780-1788.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA